During the past decade, Nagaoka Chuo General Hospital conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 2 clinical trials were completed, i.e. on average, 28.6% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nagaoka Chuo General Hospital" #1 sponsor was "Eli Lilly and Company" with 3 trials, followed by "Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan" with 3 trials sponsored, "Haruhiko Fukuda" with 2 trials sponsored, "Daiichi Sankyo Co., Ltd." with 1 trials sponsored and "Janssen Research & Development, LLC" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nagaoka Chuo General Hospital" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 2 trials as a collaborator, "Niigata University Medical & Dental Hospital" with 2 trials as a collaborator and "Tokyo Medical and Dental University" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Nagaoka Chuo General Hospital" are "Ulcerative Colitis" (4 trials), "Gastric Neoplasm" (2 trials), "Gastrointestinal Stromal Tumor" (2 trials), "Metastatic Cancer" (2 trials) and "Central Neuropathic Pain" (1 trials). Many other conditions were trialed in "Nagaoka Chuo General Hospital" in a lesser frequency.

Most popular intervention types in "Nagaoka Chuo General Hospital" are "Drug" (10 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Mirikizumab" (2 trials), "Gastrectomy with more than D2 dissection" (1 trials), "Guselkumab" (1 trials) and "K-237 0.3-0.4mg/kg (once daily)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Nagaoka Chuo General Hospital" are 12 trials for "All" genders.

Currently, there are NaN active trials in "Nagaoka Chuo General Hospital". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Nagaoka Chuo General Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Nagaoka Chuo General Hospital, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".